Three Or More Ring Hetero Atoms In The Tricyclo Ring System Patents (Class 546/82)
  • Patent number: 6699878
    Abstract: Imidazonaphthyridine compounds that are unsubstituted at the 2-position induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed.
    Type: Grant
    Filed: October 7, 2002
    Date of Patent: March 2, 2004
    Assignee: 3M Innovative Properties Company
    Inventors: Kyle J. Lindstrom, Michael J. Rice
  • Patent number: 6696460
    Abstract: Compounds of formula (1) in which the substituents have the meanings mentioned in the description, are suitable for the prevention and treatment of gastrointestinal diseases.
    Type: Grant
    Filed: March 25, 2002
    Date of Patent: February 24, 2004
    Assignee: Atlanta Pharma AG
    Inventor: Jörg Senn-Bilfinger
  • Patent number: 6696461
    Abstract: Compounds of formula (I) in which the substituents as defined in the description are useful for preventing and treating gastrointestinal disorders.
    Type: Grant
    Filed: October 4, 2002
    Date of Patent: February 24, 2004
    Assignee: Altana Pharma AG
    Inventors: Jörg Senn-Bilfinger, Wilm Buhr, Reinhard Huber, Ernst Sturm
  • Patent number: 6693113
    Abstract: The imidazonaphthyridine compound, 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine, induces the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compound exhibits antiviral and antitumor properties. Methods of preparing the compound and intermediates useful in the preparation of the compound are also disclosed.
    Type: Grant
    Filed: June 27, 2002
    Date of Patent: February 17, 2004
    Assignee: 3M Innovative Properties Company
    Inventor: Kyle J. Lindstrom
  • Publication number: 20040023932
    Abstract: Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed.
    Type: Application
    Filed: April 3, 2003
    Publication date: February 5, 2004
    Applicant: 3M Innovative Properties Company
    Inventors: John F. Gerster, Kyle J. Lindstrom, Stephen L. Crooks, Philip D. Heppner, Gregory J. Marszalek, Peter V. Maye, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
  • Publication number: 20040024008
    Abstract: The present invention provides a compound of formula I and the use thereof for the immunotherapeutic treatment of transplant rejection or autoimmune disease.
    Type: Application
    Filed: July 28, 2003
    Publication date: February 5, 2004
    Applicant: Wyeth
    Inventors: Neal Jeffrey Green, Jason Shaoyun Xiang, Audrey Molina Davies, Lihren Chen
  • Patent number: 6686472
    Abstract: Methods of preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines are disclosed. These compounds function as antiviral agents, they induce the biosynthesis of various cytokines including interferon, and they inhibit tumor formation in animal models.
    Type: Grant
    Filed: May 13, 2003
    Date of Patent: February 3, 2004
    Assignee: 3M Innovative Properties Company
    Inventors: John F. Gerster, Stephen L. Crooks, Kyle J. Lindstrom
  • Patent number: 6686373
    Abstract: This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof wherein the dashed lines represent optional double bonds; C1, C2, C3 and C4 are carbon atom; R1 is C1-4 alkyl; R2 is H, amino, etc.; R3 is H, halo-CH2—, C2-8 alkyl or Q1-, wherein said C2-8 alkyl is optionally substituted with up to 3 substituents selected from halo, C1-3 alkyl, R4(R5)N, etc.; R4 is H, C1-7 alkyl, etc.; R5 is H, C1-7alkyl, etc.; R6 and R7 are independently selected from H and C1-4 alkyl; R8 is aryl or heteroaryl; Q1 is a 4-12 membered monocyclic or bicyclic aromatic, partially saturated or fully saturated ring optionally containing up to 4 heteroatoms selected from O, N and S, and is optionally substituted with halo, C1-4 alkyl, etc.; Y5, Y6, Y7 and Y8 are hydrogen; Y1, Y2, Y3 and Y4 are independently selected from hydrogen, halo, etc.
    Type: Grant
    Filed: July 9, 2002
    Date of Patent: February 3, 2004
    Assignee: Warner-Lambert Company LLC
    Inventors: Kiyoshi Kawamura, Sachiko Mihara, Seiji Nukui, Chikara Uchida
  • Publication number: 20040019048
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain urea, thiourea, acylurea, or sulfonylurea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Application
    Filed: February 20, 2003
    Publication date: January 29, 2004
    Applicant: 3M Innovative Properties Company
    Inventors: Stephen L. Crooks, George W. Griesgraber, Kyle J. Lindstrom, Bryon A. Merrill, Michael J. Rice
  • Patent number: 6683088
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and sulfonamide or sulfamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: January 27, 2004
    Assignee: 3M Innovative Properties Company
    Inventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill, Ralph R. Roberts, Ai-Ping Wei
  • Publication number: 20040014754
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain urea, thiourea, acylurea, or sulfonylurea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Application
    Filed: January 28, 2003
    Publication date: January 22, 2004
    Applicant: 3M Innovative Properties Company
    Inventors: Stephen L. Crooks, Bryon A. Merrill, Michael J. Rice
  • Patent number: 6677349
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain sulfonamide or sulfonamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: April 28, 2003
    Date of Patent: January 13, 2004
    Assignee: 3M Innovative Properties Company
    Inventor: George W. Griesgraber
  • Patent number: 6677348
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and aryl or alkenyl functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: June 7, 2002
    Date of Patent: January 13, 2004
    Assignee: 3M Innovative Properties Company
    Inventors: Phillip D. Heppner, Leslie J. Charles, Joseph F. Dellaria, Bryon A. Merrill, John W. Mickelson
  • Patent number: 6677347
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and sulfonamide or sulfamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: June 7, 2002
    Date of Patent: January 13, 2004
    Assignee: 3M Innovative Properties Company
    Inventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill, Ralph R. Roberts, Ai-Ping Wei
  • Publication number: 20040006098
    Abstract: Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed.
    Type: Application
    Filed: April 2, 2003
    Publication date: January 8, 2004
    Applicant: 3M Innovative Properties Company
    Inventors: John F. Gerster, Kyle J. Lindstrom, Stephen L. Crooks, Philip D. Heppner, Gregory J. Marszalek, Peter V. Maye, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
  • Patent number: 6670373
    Abstract: The present invention relates to a compound of formula (I), which is useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.
    Type: Grant
    Filed: July 2, 2002
    Date of Patent: December 30, 2003
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Douglas Webb Johnson, Peter Ambrose Lander, Mark Christopher Lohman, Vinod Francis Patel, Sreenivasarao Vepachedu, Yongping Xie
  • Patent number: 6670371
    Abstract: Disclosed are compounds of the formula: wherein Ar is optionally substituted aryl or heteroaryl R1 is hydrogen or alkyl; R7 is hydrogen or alkyl; R2 is hydrogen, halogen, alkyl or alkoxy; or R1 and R2 taken together with the ring to which they are attached form a 5-9 membered saturated or aromatic ring optionally having a hetero atom selected from oxygen, sulfur or nitrogen; R3 and R4 are independently hydrogen, alkyl, cycloalkyl, aryl or heteroaryl groups; or R3 and R4 together with the nitrogen atom to which they are attached form a 5-8 membered ring; and R5 is hydrogen, halogen, straight or branched chain lower alkyl having 1-6 carbon atoms, or straight or branched chain lower alkoxy or thioalkoxy having 1-6 carbon atoms, which compounds are highly selective partial agonists or antagonists at human Corticotropin-Releasing Factor 1 (CRF1) receptors and are useful in the diagnosis and treatment of treating stress related disorders such as post trumatic stress disorder (PTSD) as wel
    Type: Grant
    Filed: March 12, 2002
    Date of Patent: December 30, 2003
    Assignee: Neurogen Corporation
    Inventors: Raymond F. Horvath, Alan Hutchison
  • Patent number: 6670372
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and aryl or alkenyl functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: December 30, 2003
    Assignee: 3M Innovative Properties Company
    Inventors: Leslie J. Charles, Joseph F. Dellaria, Philip D. Heppner, Bryon A. Merrill, John W. Mickelson
  • Patent number: 6667312
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain thioether functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: June 7, 2002
    Date of Patent: December 23, 2003
    Assignee: 3M Innovative Properties Company
    Inventors: Jason D. Bonk, Joseph F. Dellaria, Bryon A. Merrill, Matthew R. Radmer
  • Patent number: 6667405
    Abstract: Disclosed is a compound represented by the following formula (I): wherein Z1 represents an atomic group necessary to form a 5- or 6-membered nitrogen-containing heterocyclic ring; Z2 represents an atomic group necessary to form a 5- or 6-membered heterocyclic ring, Z2 may further be substituted, or may be condensed with a hetero ring or a benzene ring; R1 represents a hydrogen atom, a halogen atom, a mercapto group, an alkyl group, an alkenyl group, an aryl group, an alkylthio group, an alkenylthio group, or an arylthio group; L1 and L2 each represents a methine group; p1 represents 0 or 1; V1 represents a substituent; and n represents 0, 1 or 2, and when n represents 2, a plurality of V1 may be the same or different.
    Type: Grant
    Filed: November 1, 2001
    Date of Patent: December 23, 2003
    Assignee: Fuji Photo Film Co., Ltd.
    Inventors: Katsumi Kobayashi, Takashi Katoh, Junji Nishigaki
  • Publication number: 20030232847
    Abstract: The present invention discloses compounds corresponding to formula I: 1
    Type: Application
    Filed: April 3, 2003
    Publication date: December 18, 2003
    Inventors: David Michael Goldstein, Ronald Charles Hawley, Alfred Sui-Ting Lui, Eric Brian Sjogren
  • Patent number: 6664260
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and heterocyclyl or heteroaryl functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: December 16, 2003
    Assignee: 3M Innovative Properties Company
    Inventors: Leslie J. Charles, Joseph F. Dellaria, George W. Griesgraber, Philip D. Heppner, Karl J. Manske, John W. Mickelson, Michael J. Rice
  • Patent number: 6664264
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain thioether functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: December 16, 2003
    Assignee: 3M Innovative Properties Company
    Inventors: Joseph F. Dellaria, Bryon A. Merrill, Matthew R. Radmer
  • Patent number: 6664265
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: June 7, 2002
    Date of Patent: December 16, 2003
    Assignee: 3M Innovative Properties Company
    Inventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Byron A. Merrill
  • Patent number: 6660747
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: December 9, 2003
    Assignee: 3M Innovative Properties Company
    Inventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill
  • Patent number: 6660735
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and urea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: June 7, 2002
    Date of Patent: December 9, 2003
    Assignee: 3M Innovative Properties Company
    Inventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill
  • Patent number: 6656938
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and urea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: December 2, 2003
    Assignee: 3M Innovative Properties Company
    Inventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill
  • Publication number: 20030216429
    Abstract: The present invention is directed to novel 7-heterocyclyl quinoline and thieno[2,3-b]pyridine derivatives of the general formula (I) or (II) 1
    Type: Application
    Filed: April 3, 2003
    Publication date: November 20, 2003
    Inventors: Zhihua Sui, Mark Macielag, James C. Lanter
  • Publication number: 20030212092
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and aryl or alkenyl functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Application
    Filed: June 7, 2002
    Publication date: November 13, 2003
    Inventors: Philip D. Heppner, Leslie J. Charles, Joseph F. Dellaria, Bryon A. Merrill, John W. Mickelson
  • Publication number: 20030212270
    Abstract: 1-substituted, 2-substituted 1H-imidazo[4,5-c]-quinolin-4-amines are disclosed. These compounds function as antiviral agents, they induce biosynthesis of interferon, and they inhibit tumor formation in animal models. This invention also provides intermediates for preparing such compounds, pharmaceutical compositions containing such compounds, and pharmacological methods of using such compounds.
    Type: Application
    Filed: May 13, 2003
    Publication date: November 13, 2003
    Applicant: 3M Innovative Properties Company
    Inventors: John F. Gerster, Kyle J. Lindstrom
  • Publication number: 20030212091
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and aryl or alkenyl functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Application
    Filed: December 6, 2001
    Publication date: November 13, 2003
    Inventors: Leslie J. Charles, Joseph F. Dellaria, Philip D. Heppner, Bryon A. Merrill, John W. Mickelson
  • Publication number: 20030212093
    Abstract: Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed.
    Type: Application
    Filed: October 7, 2002
    Publication date: November 13, 2003
    Applicant: 3M Innovative Properties Company
    Inventors: John F. Gerster, Kyle J. Lindstrom, Stephen L. Crooks, Philip D. Heppner, Gregory J. Marszalek, Peter V. Maye, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
  • Patent number: 6642222
    Abstract: The present invention provides novel compounds of formula I which may be useful in hyperpolarizing cell membranes, opening potassium channels, relaxing smooth muscle cells, and inhibiting bladder contractions.
    Type: Grant
    Filed: May 3, 2000
    Date of Patent: November 4, 2003
    Assignee: Abbott Laboratories
    Inventors: William A. Carroll, Konstantinos A. Agrios, Robert J. Altenbach, Irene Drizin, Michael E. Kort
  • Patent number: 6642249
    Abstract: The present invention relates to a novel heterocyclic compound, a pharmaceutical composition comprisining said compound, a method and use of said compound for clinical treatment of medical conditions which may benefit from immunomodulation, e.g. rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28. A method of screening compounds for their ability of inhibiting ligand-induced co-stimulatory receptor internalization pathways in immune competent human cells is described. Said immune competent human cells are incubated at conditions capable of inducing co-stimulatory receptor internalization in the presence of at least one test compound and the suppression of the ligand-induced co-stimulatory receptor internalization determined.
    Type: Grant
    Filed: June 26, 2002
    Date of Patent: November 4, 2003
    Assignee: Active Biotech AB
    Inventors: Per Axel Björk, Tomas Fex, Lars Olof Göran Pettersson, Pous Sørensen, Dorthe Da Graça Thrige
  • Publication number: 20030203901
    Abstract: The invention relates to certain indolinone compounds, their method of synthesis, and a combinatorial library consisting of the indolinone compounds. The invention also relates to methods of modulating the function of protein tyrosine kinases using indolinone compounds and methods of treating diseases by modulating the function of protein tyrosine kinases and related signal transduction pathways.
    Type: Application
    Filed: November 25, 2002
    Publication date: October 30, 2003
    Applicant: SUGEN, INC.
    Inventors: Peng Cho Tang, Li Sun
  • Patent number: 6638944
    Abstract: Imidazonaphthyridine compounds that have a urea containing substituent at the 1-position induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed.
    Type: Grant
    Filed: June 27, 2002
    Date of Patent: October 28, 2003
    Assignee: 3M Innovative Properties Company
    Inventor: John W. Mickelson
  • Patent number: 6635759
    Abstract: The invention relates to a substituted 4-trifluoromethyl carbostyril according to formula (I) and is characterised in that the 4-trifluoromethyl carbostyril is provided with an absorption maximum between 350 and 420 nm and a luminescence maximum between 430 and 900 nm. The molecule can be substituted with groups that are useful for complexing metal ions and/or for binding the molecule to relevant groups of a target molecule or a solid supporting material. The carbostyril as described above can inter alia serve as an antenna molecule of a lanthanide complex. Said complexes can be templates and can be brought into contact with a directly bound or free colour molecule which absorbs in the rant of 580-710 nm. Luminescence effects and decay periods can be measured after the contact with a relevant analyte.
    Type: Grant
    Filed: December 31, 2001
    Date of Patent: October 21, 2003
    Inventors: Georg Uray, Karlheinz Niederreiter
  • Patent number: 6632809
    Abstract: The present invention relates to compounds of the formula I: or a pharmaceutically acceptable derivative or prodrug thereof. The compounds are useful as inhibitors of bacterial gyrase activity. The present invention also relates to methods for treating bacterial infections in mammala. The present invention also relates to methods for decreasing bacterial quantity in a biological sample.
    Type: Grant
    Filed: December 12, 2001
    Date of Patent: October 14, 2003
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Anne-Laure Grillot, Paul Charifson, Dean Stamos, Yusheng Liao, Michael Badia, Martin Trudeau
  • Patent number: 6630588
    Abstract: Dye labeled imidazonaphthyridine, imidazopyridine and imidazoquinoline compounds having immune response modulating activity are disclosed. The compounds are useful, inter alia, for determining the binding and/or receptor sites of the molecules.
    Type: Grant
    Filed: February 19, 2002
    Date of Patent: October 7, 2003
    Assignee: 3M Innovative Properties Company
    Inventors: Michael J. Rice, Mark A. Tomai, Ai-Ping Wei
  • Publication number: 20030187016
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Application
    Filed: June 7, 2002
    Publication date: October 2, 2003
    Inventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill
  • Publication number: 20030186082
    Abstract: This invention features a dipyrazolo-pyridine compound of formula (I): 1
    Type: Application
    Filed: November 14, 2002
    Publication date: October 2, 2003
    Inventors: Yu-Tai Tao, Chung-Wen Ko, Chang-Hao Chuen, Jing-Wen Peng
  • Patent number: 6627638
    Abstract: Thiazolo-, oxazolo- and selenazolo[4,5-c]quinolin-4-amines and analogs thereof are described including methods of manufacture and the use of novel intermediates. The compounds are immunomodulators and induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor, and inhibit the T-helper-type 2 immune response. The compounds are further useful in the treatment of viral and neoplastic diseases.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: September 30, 2003
    Assignee: 3M Innovative Properties Company
    Inventors: John F. Gerster, Kyle J. Lindstrom, Gregory J. Marszalek, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
  • Publication number: 20030181455
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: January 28, 2003
    Publication date: September 25, 2003
    Applicant: Neurogen Corporation, A Corporation of the State of Delaware
    Inventors: Jun Yuan, Pamela Albaugh, Kenneth Shaw, Alan Hutchison
  • Patent number: 6624172
    Abstract: Imidazonaphthydrine compounds that have an aryl containing substituent at the 1-position induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed.
    Type: Grant
    Filed: August 31, 2001
    Date of Patent: September 23, 2003
    Assignee: 3M Innovative Properties Company
    Inventors: Kyle J. Lindstrom, Bryon A. Merrill, Michael J. Rice
  • Patent number: 6624305
    Abstract: A process for preparing 1H-imidazo[4,5-c]quinolin-4-amines is disclosed. The process involves reacting a 6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline with triphenylphosphine and hydrolyzing the product thereof.
    Type: Grant
    Filed: February 6, 2003
    Date of Patent: September 23, 2003
    Assignee: 3M Innovative Properties Company
    Inventors: John F. Gerster, Kyle J. Lindstrom
  • Publication number: 20030171394
    Abstract: Compounds of formula I 1
    Type: Application
    Filed: January 22, 2003
    Publication date: September 11, 2003
    Inventors: Irene Drizin, Robert J. Altenbach, William A. Carroll
  • Publication number: 20030166929
    Abstract: Disclosed are novel compounds of formula (I): 1
    Type: Application
    Filed: November 12, 2002
    Publication date: September 4, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Roger John Snow, Mario G. Cardozo, Daniel R. Goldberg, Abdelhakim Hammach, Tina M. Morwick, Neil Moss, Usha R. Patel, Anthony S. Prokopowicz, Hindenori Takahashi, Matt Aaron Tschantz, Xiao-Jun Wang
  • Patent number: 6613902
    Abstract: A process for preparing 1H-imidazo[4,5-c]quinolin-4-amines is disclosed. The process involves reacting a 6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline with triphenylphosphine and hydrolyzing the product thereof.
    Type: Grant
    Filed: January 28, 2003
    Date of Patent: September 2, 2003
    Assignee: 3M Innovative Properties Company
    Inventors: John F. Gerster, Kyle J. Lindstrom
  • Publication number: 20030158193
    Abstract: Compounds of the formula 1 1
    Type: Application
    Filed: September 27, 2002
    Publication date: August 21, 2003
    Inventors: J?ouml;rg Senn-Bilfinger, Wilm Buhr
  • Publication number: 20030158192
    Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and urea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    Type: Application
    Filed: December 6, 2001
    Publication date: August 21, 2003
    Inventors: Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill